[{"id":"1ba644d9-46af-4d81-be0f-6a946f789cac","acronym":"","url":"https://clinicaltrials.gov/study/NCT05539365","created_at":"2022-09-14T18:56:14.616Z","updated_at":"2025-02-25T17:38:04.297Z","phase":"Phase 2","brief_title":"Dendritic Cell-Based Treatment Plus Immunotherapy for the Treatment of Metastatic or Unresectable Triple Negative Breast Cancer","source_id_and_acronym":"NCT05539365","lead_sponsor":"Roswell Park Cancer Institute","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression • PD-L1 negative","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • PD-L1 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • aDC1 vaccine"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 02/01/2025","start_date":" 02/01/2025","primary_txt":" Primary completion: 02/01/2027","primary_completion_date":" 02/01/2027","study_txt":" Completion: 02/01/2027","study_completion_date":" 02/01/2027","last_update_posted":"2025-01-29"},{"id":"aff3e72a-a029-43e5-b059-ba3db87de101","acronym":"","url":"https://clinicaltrials.gov/study/NCT05127824","created_at":"2021-11-19T12:53:43.443Z","updated_at":"2024-07-02T16:34:26.105Z","phase":"Phase 2","brief_title":"Autologous Dendritic Cell Vaccine in Kidney Cancer","source_id_and_acronym":"NCT05127824","lead_sponsor":"Jodi Maranchie","biomarkers":" ER • CD8 • PD-1 • IFNG • LAG3 • TIGIT • LAMP3 • GZMB • BTLA • CD31 • NRP1 • PECAM1 • ANXA5","pipe":"","alterations":" ","tags":["ER • CD8 • PD-1 • IFNG • LAG3 • TIGIT • LAMP3 • GZMB • BTLA • CD31 • NRP1 • PECAM1 • ANXA5"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Cabometyx (cabozantinib tablet) • Cometriq (cabozantinib capsule) • aDC1 vaccine"],"overall_status":"Recruiting","enrollment":" Enrollment 42","initiation":"Initiation: 07/06/2023","start_date":" 07/06/2023","primary_txt":" Primary completion: 12/01/2026","primary_completion_date":" 12/01/2026","study_txt":" Completion: 12/01/2026","study_completion_date":" 12/01/2026","last_update_posted":"2024-06-14"},{"id":"7751beea-ed0b-4a4d-8397-acffe8af0a14","acronym":"","url":"https://clinicaltrials.gov/study/NCT02432378","created_at":"2021-01-18T11:38:27.441Z","updated_at":"2024-07-02T16:35:00.114Z","phase":"Phase 1/2","brief_title":"Intensive Locoregional Chemoimmunotherapy for Recurrent Ovarian Cancer Plus Intranodal DC Vaccines","source_id_and_acronym":"NCT02432378","lead_sponsor":"Roswell Park Cancer Institute","biomarkers":" IFNG • CXCL10 • CXCL12 • CXCL9 • CD4 • IL10 • CXCL11 • CCL2 • ITGAM • FOXP3 • CCL22 • CCL3 • ITGAX","pipe":"","alterations":" ","tags":["IFNG • CXCL10 • CXCL12 • CXCL9 • CD4 • IL10 • CXCL11 • CCL2 • ITGAM • FOXP3 • CCL22 • CCL3 • ITGAX"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • Ampligen (rintatolimod) • aDC1 vaccine • celecoxib oral"],"overall_status":"Suspended","enrollment":" Enrollment 25","initiation":"Initiation: 09/04/2015","start_date":" 09/04/2015","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 06/01/2026","study_completion_date":" 06/01/2026","last_update_posted":"2024-05-30"},{"id":"8e13ae6f-2afc-43dc-b06c-933f9e190424","acronym":"","url":"https://clinicaltrials.gov/study/NCT04093323","created_at":"2023-11-30T22:15:48.537Z","updated_at":"2024-07-02T16:35:00.203Z","phase":"Phase 2","brief_title":"Polarized Dendritic Cell (aDC1) Based Treatment, Interferon Alpha-2, Rintatolimod, and Celecoxib for the Treatment of HLA-A2+ Refractory Melanoma","source_id_and_acronym":"NCT04093323","lead_sponsor":"Roswell Park Cancer Institute","biomarkers":" CD8","pipe":" | ","alterations":" CD8 positive","tags":["CD8"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD8 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Intron A (interferon α-2b) • Ampligen (rintatolimod) • aDC1 vaccine • celecoxib oral"],"overall_status":"Recruiting","enrollment":" Enrollment 24","initiation":"Initiation: 06/20/2024","start_date":" 06/20/2024","primary_txt":" Primary completion: 08/22/2025","primary_completion_date":" 08/22/2025","study_txt":" Completion: 08/22/2025","study_completion_date":" 08/22/2025","last_update_posted":"2024-05-30"},{"id":"00649577-c618-480b-a586-d53685647f37","acronym":"","url":"https://clinicaltrials.gov/study/NCT03735589","created_at":"2021-01-18T18:17:50.902Z","updated_at":"2024-07-02T16:35:28.338Z","phase":"Phase 1/2","brief_title":"Specialized Immune Cells (nCTLs) and a Vaccine (Alpha-type-1 Polarized Dendritic Cells) in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer","source_id_and_acronym":"NCT03735589","lead_sponsor":"Roswell Park Cancer Institute","biomarkers":" CD8","pipe":"","alterations":" ","tags":["CD8"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e aDC1 vaccine"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 12/15/2023","start_date":" 12/15/2023","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2023-11-22"},{"id":"632fb149-e532-4ce8-97f0-1b7e2005cc25","acronym":"","url":"https://clinicaltrials.gov/study/NCT05589844","created_at":"2022-10-21T13:55:52.531Z","updated_at":"2024-07-02T16:35:49.509Z","phase":"Phase 1b","brief_title":"A Cytomegalovirus-Directed Vaccine (CMV-alphaDC1) for Preventing Cytomegalovirus Infection or Reactivation in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation","source_id_and_acronym":"NCT05589844","lead_sponsor":"Roswell Park Cancer Institute","biomarkers":" IFNG","pipe":"","alterations":" ","tags":["IFNG"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e aDC1 vaccine"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 03/01/2023","start_date":" 03/01/2023","primary_txt":" Primary completion: 11/16/2024","primary_completion_date":" 11/16/2024","study_txt":" Completion: 11/16/2025","study_completion_date":" 11/16/2025","last_update_posted":"2023-04-27"},{"id":"7598cb50-7991-494b-83ca-7ad86fadd6da","acronym":"","url":"https://clinicaltrials.gov/study/NCT02479230","created_at":"2022-11-22T17:57:19.713Z","updated_at":"2024-07-02T16:36:00.106Z","phase":"Phase 1","brief_title":"Type I-Polarized Autologous Dendritic Cell Vaccine With Tumor Blood Vessel Antigen-Derived Peptides in Metastatic Breast Cancer Patients","source_id_and_acronym":"NCT02479230","lead_sponsor":"Joseph Baar, MD, PhD","biomarkers":" IFNG","pipe":"","alterations":" ","tags":["IFNG"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e gemcitabine • aDC1 vaccine"],"overall_status":"Completed","enrollment":" Enrollment 18","initiation":"Initiation: 07/17/2015","start_date":" 07/17/2015","primary_txt":" Primary completion: 10/30/2019","primary_completion_date":" 10/30/2019","study_txt":" Completion: 07/01/2022","study_completion_date":" 07/01/2022","last_update_posted":"2022-11-22"},{"id":"d160bba2-646c-4438-b590-5eb0c74d7442","acronym":"","url":"https://clinicaltrials.gov/study/NCT02151448","created_at":"2021-01-18T09:59:55.040Z","updated_at":"2024-07-02T16:36:43.024Z","phase":"Phase 1/2","brief_title":"αDC1 Vaccine + Chemokine Modulatory Regimen (CKM) as Adjuvant Treatment of Peritoneal Surface Malignancies","source_id_and_acronym":"NCT02151448","lead_sponsor":"David Bartlett","biomarkers":" IL6 • TNFA • CXCL8 • CXCL10 • CXCL12 • IL10 • CXCL11","pipe":" | ","alterations":" IL10 elevation","tags":["IL6 • TNFA • CXCL8 • CXCL10 • CXCL12 • IL10 • CXCL11"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IL10 elevation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Intron A (interferon α-2b) • Ampligen (rintatolimod) • aDC1 vaccine • celecoxib oral"],"overall_status":"Completed","enrollment":" Enrollment 64","initiation":"Initiation: 07/01/2014","start_date":" 07/01/2014","primary_txt":" Primary completion: 02/18/2019","primary_completion_date":" 02/18/2019","study_txt":" Completion: 02/18/2019","study_completion_date":" 02/18/2019","last_update_posted":"2020-07-20"},{"id":"284ff763-35c2-4324-a098-fcf67bc5ba64","acronym":"","url":"https://clinicaltrials.gov/study/NCT02615574","created_at":"2021-01-18T12:42:48.078Z","updated_at":"2024-07-02T16:37:17.536Z","phase":"Phase 2","brief_title":"A Study of Type-1 Polarized Dendritic Cell (αDC1) Vaccine in Combination With Tumor-Selective Chemokine Modulation (Interferon-α2b, Rintatolimod, and Celecoxib) in Subjects With Chemo-Refractory Metastatic Colorectal Cancer","source_id_and_acronym":"NCT02615574","lead_sponsor":"Pawel Kalinski","biomarkers":" KRAS","pipe":" | ","alterations":" KRAS wild-type • RAS wild-type • HLA-A2 positive","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS wild-type • RAS wild-type • HLA-A2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ampligen (rintatolimod) • aDC1 vaccine • celecoxib oral"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 03/01/2016","start_date":" 03/01/2016","primary_txt":" Primary completion: 06/01/2018","primary_completion_date":" 06/01/2018","study_txt":" Completion: 12/01/2018","study_completion_date":" 12/01/2018","last_update_posted":"2017-09-26"}]